Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Breakfree-AiCE: Zolacabtagene Autoleucel (Zola-cel) in Chronic Immune Thrombocytopenia and Autoimmune Hemolytic Anemia
2025-524993-41-00Phase 2Authorised
- Sponsor
- Celgene Corporation
- Start
- Aug 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of BMS-986353 in immune thrombocytopenia (ITP) and autoimmune haemolytic anaemia (AIHA), sponsored by Celgene Corporation. Primary endpoints: Primary: Safety and Primary: Blood problem improvement. Planned start Aug 2026; status: authorised.
02
Drugs
BMS-986353
03
Conditions
immune thrombocytopenia (ITP)autoimmune haemolytic anaemia (AIHA)
Beyond the preview
Go deeper on 2025-524993-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524993-41-00.